Adjuvant Breast, Breast
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Eligible for screening study DCP 001
Site Delegation of Tasks Log required prior to registration of any patients.
Effective June 23, 2020, the BAHO substudy for SWOG study S1418/BR006, is permanently closed to accrual.